Compare Honest Company Inc (HNST) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs Novartis AG — how do they compare? Honest Company Inc trades at $5.07 (market cap $533.20M), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 503.7× Honest Company Inc's market cap, and Novartis AG pays a 3.31% dividend while Honest Company Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honest Company Inc for 39 Days and Novartis AG for 82 Days on average.
| HNST | NVS | |
|---|---|---|
Market Cap | $533.20M | $268.57B |
Volume | 1,990,155 | 1,532,573 |
Sector | Consumer Staples | Health |
52-Week High | $5.95 | $168.62 |
52-Week Low | $2.10 | $121.80 |
Typical Hold Time | 39 Days | 82 Days |
Enterprise Value | $436.81M | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $4.97, up 0.81% with a bearish technical outlook despite recent institutional buying. The company shows mixed fundamentals with Q2 2026 earnings beating estimates but negative profit margins and declining revenue guidance for 2026. Analyst consensus is cautious with a $5.30 price target and 30% buy rating distribution.
The stock faces headwinds from negative profitability and competitive pressures, though strategic exits show early turnaround signs. Upside potential exists if margin improvements continue, but investors should weigh execution risks against institutional accumulation trends.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
